© 1999 Oxford University Press
Article |
The mutagenicity of benzo[a]pyrene in mouse small intestine
Cancer Research Campaign Human Cancer Genetics Research Group, Cambridge Institute for Medical Research, Box 139, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2XY and
1 Department of Clinical Pharmacology, Royal Postgraduate Medical School, DuCane Road, London W12 0NN, UK
We have investigated the mutagenicity of benzo[a]pyrene (B[a]P) in small intestine using the Dlb-1 locus assay in the mouse. Administration of B[a]P by the oral and i.p. routes had markedly different effects on the number of Dlb-1 mutations and the pattern of induction of cytochrome P-4501A1 (CYP1A1). In Ahr-responsive animals i.p. injection resulted in marked induction in crypt cells along the length of the small intestine, with some induction in the villus cells. In contrast, after oral administration, CYP1A1 induction was evident only in the villus cells, and this declined distally. The intensity and speed of induction in Ahr-responsive animals was such that the genotoxic effect of a single injection of B[a]P could not be augmented by prior treatment with non-genotoxic inducers such as ß-napthoflavone and TCDD. Oral B[a]P treatment resulted in a decrease in the number of mutations when compared with the i.p. route. Studies in congenic Ahr-non-responsive versus Ahr-responsive mice indicated that induction of CYP1A1 was associated with increased numbers of Dlb-1 mutations. Mutation induction in Ahr-non-responsive mice in the absence of detectable CYP1A1 in either liver or small intestine indicates that an appreciable portion of B[a]P activation to a genotoxin must be by other than a CYP1A1 mediated route. These data show that B[a]P is a potent small intestinal mutagen at the Dlb-1 locus.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. De Buck, P. Augustijns, and C. P. Muller Specific Antibody Modulates Absorptive Transport and Metabolic Activation of Benzo[a]pyrene across Caco-2 Monolayers J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 640 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ramesh, S. A. Walker, D. B. Hood, M. D. Guillen, K. Schneider, and E. H. Weyand Bioavailability and Risk Assessment of Orally Ingested Polycyclic Aromatic Hydrocarbons International Journal of Toxicology, September 1, 2004; 23(5): 301 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Kaminsky and Q.-Y. Zhang THE SMALL INTESTINE AS A XENOBIOTIC-METABOLIZING ORGAN Drug Metab. Dispos., December 1, 2003; 31(12): 1520 - 1525. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mori, A. Koide, Y. Kobayashi, F. Furukawa, M. Hirose, and A. Nishikawa Effects of cigarette smoke and a heterocyclic amine, MeIQx on cytochrome P-450, mutagenic activation of various carcinogens and glucuronidation in rat liver Mutagenesis, January 1, 2003; 18(1): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Shane, J. de Boer, D. E. Watson, J. K. Haseman, B. W. Glickman, and K. R. Tindall LacI mutation spectra following benzo[a]pyrene treatment of Big Blue(R) mice Carcinogenesis, April 1, 2000; 21(4): 715 - 725. [Abstract] [Full Text] [PDF]
|
|